IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v9y2018i1d10.1038_s41467-018-03421-7.html
   My bibliography  Save this article

Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults

Author

Listed:
  • Christopher R. Martens

    (University of Colorado Boulder)

  • Blair A. Denman

    (University of Colorado Boulder)

  • Melissa R. Mazzo

    (University of Colorado Boulder)

  • Michael L. Armstrong

    (University of Colorado Anschutz Medical Campus)

  • Nichole Reisdorph

    (University of Colorado Anschutz Medical Campus)

  • Matthew B. McQueen

    (University of Colorado Boulder)

  • Michel Chonchol

    (University of Colorado Anschutz Medical Campus)

  • Douglas R. Seals

    (University of Colorado Boulder)

Abstract

Nicotinamide adenine dinucleotide (NAD+) has emerged as a critical co-substrate for enzymes involved in the beneficial effects of regular calorie restriction on healthspan. As such, the use of NAD+ precursors to augment NAD+ bioavailability has been proposed as a strategy for improving cardiovascular and other physiological functions with aging in humans. Here we provide the evidence in a 2 × 6-week randomized, double-blind, placebo-controlled, crossover clinical trial that chronic supplementation with the NAD+ precursor vitamin, nicotinamide riboside (NR), is well tolerated and effectively stimulates NAD+ metabolism in healthy middle-aged and older adults. Our results also provide initial insight into the effects of chronic NR supplementation on physiological function in humans, and suggest that, in particular, future clinical trials should further assess the potential benefits of NR for reducing blood pressure and arterial stiffness in this group.

Suggested Citation

  • Christopher R. Martens & Blair A. Denman & Melissa R. Mazzo & Michael L. Armstrong & Nichole Reisdorph & Matthew B. McQueen & Michel Chonchol & Douglas R. Seals, 2018. "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults," Nature Communications, Nature, vol. 9(1), pages 1-11, December.
    • Handle: RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-03421-7
    DOI: 10.1038/s41467-018-03421-7
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-018-03421-7
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-018-03421-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Mary M. McDermott & Christopher R. Martens & Kathryn J. Domanchuk & Dongxue Zhang & Clara B. Peek & Michael H. Criqui & Luigi Ferrucci & Philip Greenland & Jack M. Guralnik & Karen J. Ho & Melina R. K, 2024. "Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial," Nature Communications, Nature, vol. 15(1), pages 1-11, December.
    2. Haakon Berven & Simon Kverneng & Erika Sheard & Mona Søgnen & Solveig Amdahl Af Geijerstam & Kristoffer Haugarvoll & Geir-Olve Skeie & Christian Dölle & Charalampos Tzoulis, 2023. "NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    3. Eliot L. Sherman, 2020. "Discretionary Remote Working Helps Mothers Without Harming Non-mothers: Evidence from a Field Experiment," Management Science, INFORMS, vol. 66(3), pages 1351-1374, March.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-03421-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.